Management and Treatment of Lennox-Gastaut Syndrome

Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy characterised by multiple seizure types, a distinctive slow spike-wave electroencephalographic pattern and plateauing or decline in cognitive development. Management revolves around multidisciplinary care and individualised regimens combining pharmacological and non-pharmacological strategies. First-line therapy typically involves broad-spectrum antiepileptic drugs such as sodium valproate, with adjunctive agents including lamotrigine, rufinamide, clobazam and newer modalities such as cannabidiol or fenfluramine in selected cases. Treatment decisions account for seizure types, co-morbidities, adverse-effect profiles and quality-of-life considerations. When pharmacotherapy remains insufficient, dietary therapy (notably the ketogenic diet), neuromodulation via vagus nerve stimulation or resective and disconnective epilepsy surgery (including corpus callosotomy) are incorporated early in the care plan. Regular reassessment by an epilepsy specialist ensures adaptation of treatment algorithms to evolving seizure patterns and developmental needs. Emerging research aims both to clarify underlying network mechanisms and to expand the therapeutic arsenal with targeted small molecules and gene-based approaches. Despite advances, seizure remission remains uncommon, emphasising that optimisation of cognitive, behavioural and social function is a core treatment objective alongside seizure control.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management and Treatment of Lennox-Gastaut Syndrome publication trend

The graph below shows the total number of articles in management and treatment of lennox-gastaut syndrome across all publications each year (not limited to Nature Index journals).

Technical terms

Lennox-Gastaut syndrome (LGS): A severe childhood-onset epileptic encephalopathy marked by multiple resistant seizure types and cognitive impairment.

Developmental and epileptic encephalopathy (DEE): A group of disorders in which epileptic activity contributes to progressive developmental delay or regression.

Electroencephalogram (EEG): A non-invasive recording of electrical brain activity used to characterise seizure patterns.

Sodium valproate: A broad-spectrum antiepileptic drug often used as first-line therapy in LGS.

Vagus nerve stimulation (VNS): A neuromodulatory treatment involving implanted electrodes to reduce seizure frequency.

Ketogenic diet: A high-fat, low-carbohydrate dietary therapy that alters cerebral metabolism to diminish seizure activity.

References

1. GABAA Receptor β3 Subunit Mutation N328D Heterozygous Knock-in Mice Have Lennox–Gastaut Syndrome. International Journal of Molecular Sciences (2023).
2. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies. Epilepsy Research (2021).
3. Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations. Frontiers in Neurology (2017).
4. Conceptualizing Lennox–Gastaut Syndrome as a Secondary Network Epilepsy. Frontiers in Neurology (2014).
5. Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder. Frontiers in Neurology (2021).